Caribou Biosciences Showcases Promising Phase 1 CAR-T Cell Therapy Data at 2026 Tandem Meetings

Reuters

Feb 04

<a href="https://laohu8.com/S/CRBU">Caribou Biosciences</a> Showcases Promising Phase 1 CAR-T Cell Therapy Data at 2026 Tandem Meetings

Caribou Biosciences Inc. announced that new clinical data from its allogeneic CAR-T cell therapy programs will be presented at the 2026 Tandem Meetings of ASTCT® and CIBMTR®, taking place from February 4-7 in Salt Lake City, Utah. The company will present updated clinical and translational data for vispa-cel (CB-010) from the ANTLER phase 1 trial in relapsed or refractory B cell non-Hodgkin lymphoma, as well as for CB-011 from the CaMMouflage phase 1 trial in relapsed or refractory multiple myeloma. The CaMMouflage study data will be presented in an oral session and demonstrate a correlation between CAR-T cell expansion and deep, durable responses, supporting the regimen selected for dose expansion. These results were previously disclosed in November 2025 and will be presented with new supportive data during the meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caribou Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9648550-en) on February 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608364848"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608364848\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608364848?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608364848","market":"nz","top_or_hot":-1,"title":"Caribou Biosciences Showcases Promising Phase 1 CAR-T Cell Therapy Data at 2026 Tandem Meetings","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CRBU\">Caribou Biosciences</a> Showcases Promising Phase 1 CAR-T Cell Therapy Data at 2026 Tandem Meetings\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Caribou Biosciences Inc. announced that new clinical data from its allogeneic CAR-T cell therapy programs will be presented at the 2026 Tandem Meetings of ASTCT® and CIBMTR®, taking place from February 4-7 in Salt Lake City, Utah. The company will present updated clinical and translational data for vispa-cel (CB-010) from the ANTLER phase 1 trial in relapsed or refractory B cell non-Hodgkin lymphoma, as well as for CB-011 from the CaMMouflage phase 1 trial in relapsed or refractory multiple myeloma. The CaMMouflage study data will be presented in an oral session and demonstrate a correlation between CAR-T cell expansion and deep, durable responses, supporting the regimen selected for dose expansion. These results were previously disclosed in November 2025 and will be presented with new supportive data during the meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caribou Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9648550-en) on February 04, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Caribou Biosciences Showcases Promising Phase 1 CAR-T Cell Therapy Data at 2026 Tandem Meetings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCaribou Biosciences Showcases Promising Phase 1 CAR-T Cell Therapy Data at 2026 Tandem Meetings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-04 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CRBU\">Caribou Biosciences</a> Showcases Promising Phase 1 CAR-T Cell Therapy Data at 2026 Tandem Meetings\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Caribou Biosciences Inc. announced that new clinical data from its allogeneic CAR-T cell therapy programs will be presented at the 2026 Tandem Meetings of ASTCT® and CIBMTR®, taking place from February 4-7 in Salt Lake City, Utah. The company will present updated clinical and translational data for vispa-cel (CB-010) from the ANTLER phase 1 trial in relapsed or refractory B cell non-Hodgkin lymphoma, as well as for CB-011 from the CaMMouflage phase 1 trial in relapsed or refractory multiple myeloma. The CaMMouflage study data will be presented in an oral session and demonstrate a correlation between CAR-T cell expansion and deep, durable responses, supporting the regimen selected for dose expansion. These results were previously disclosed in November 2025 and will be presented with new supportive data during the meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caribou Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9648550-en) on February 04, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRBU","symbol_name":"Caribou Biosciences","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL6c9PSs:1","article_id":"2608364848","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608364848","pubTimestamp":1770210020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Caribou Biosciences Inc. announced that new clinical data from its allogeneic CAR-T cell therapy programs will be presented at the 2026 Tandem Meetings of ASTCT and CIBMTR, taking place from February 4-7 in Salt Lake City, Utah. The company will present updated clinical and translational data for vispa-cel  from the ANTLER phase 1 trial in relapsed or refractory B cell non-Hodgkin lymphoma, as well as for CB-011 from the CaMMouflage phase 1 trial in relapsed or refractory multiple myeloma. The CaMMouflage study data will be presented in an oral session and demonstrate a correlation between CAR-T cell expansion and deep, durable responses, supporting the regimen selected for dose expansion. These results were previously disclosed in November 2025 and will be presented with new supportive data during the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-g","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRBU":"Caribou Biosciences","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4539":"次新股","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD"},"translate_title":"Caribou Biosciences在2026年串联会议上展示了有前景的1期CAR-T细胞治疗数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRBU":0.9,"NDAQ":0.9},"content_text":"Caribou Biosciences Showcases Promising Phase 1 CAR-T Cell Therapy Data at 2026 Tandem Meetings\n    \n\n        Caribou Biosciences Inc. announced that new clinical data from its allogeneic CAR-T cell therapy programs will be presented at the 2026 Tandem Meetings of ASTCT® and CIBMTR®, taking place from February 4-7 in Salt Lake City, Utah. The company will present updated clinical and translational data for vispa-cel (CB-010) from the ANTLER phase 1 trial in relapsed or refractory B cell non-Hodgkin lymphoma, as well as for CB-011 from the CaMMouflage phase 1 trial in relapsed or refractory multiple myeloma. The CaMMouflage study data will be presented in an oral session and demonstrate a correlation between CAR-T cell expansion and deep, durable responses, supporting the regimen selected for dose expansion. These results were previously disclosed in November 2025 and will be presented with new supportive data during the meeting.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caribou Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9648550-en) on February 04, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}